Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by bit.bio

bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub

February 19, 2026

From bit.bio

Via Business Wire

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

October 16, 2024

From bit.bio

Via Business Wire

bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference

September 30, 2024

From bit.bio

Via Business Wire

bit.bio Expands Executive Team with Appointment of Przemek Obloj as Chief Financial Officer

July 31, 2024

From bit.bio

Via Business Wire

bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain

June 20, 2024

From bit.bio

Via Business Wire

Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta

April 29, 2024

From bit.bio

Via Business Wire

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

March 05, 2024

From bit.bio

Via Business Wire

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

February 28, 2024

From bit.bio

Via Business Wire

bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)

December 06, 2023

From bit.bio

Via Business Wire

Scientists at King's College London and bit.bio Collaborate to Develop Multi-Cell Models of the Human Brain With Optimised Open-Source Protocols for Use by Any Researcher

November 24, 2023

From bit.bio

Via Business Wire

bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

November 08, 2023

From bit.bio

Via Business Wire

bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery

October 17, 2023

From bit.bio

Via Business Wire

bit.bio is Industrialising Human Cell Manufacturing, Unleashing the Potential of Synthetic Biology for Reproducible Research and Affordable Regenerative Medicines

June 15, 2023

From bit.bio

Via Business Wire

bit.bio Launches New Custom Disease Model Cells Offering, Advancing Disease Research and Drug Discovery

May 23, 2023

From bit.bio

Via Business Wire

bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientist

May 11, 2023

From bit.bio

Via Business Wire

bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases

November 23, 2022

From bit.bio

Via Business Wire

bit.bio Expands Independent Ethics and Sustainability Board as Part of Commitment to Being a Purpose Driven Company

October 25, 2022

From bit.bio

Via Business Wire

bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease

September 29, 2022

From bit.bio

Via Business Wire

bit.bio named Emerging Star at European Mediscience Awards 2022

June 17, 2022

From bit.bio

Via Business Wire

bit.bio Presents Data at ISSCR Demonstrating Their Platform’s Capability to Create Any Human Cell

June 16, 2022

From bit.bio

Via Business Wire

bit.bio Celebrates Double Award Win at Cambridge Science and Technology Awards 2022 Including Biotech of the Year for the Second Time in a Row

May 23, 2022

From bit.bio

Via Business Wire

bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening

May 09, 2022

From bit.bio

Via Business Wire

Bit.bio Appoints Accomplished Biotechnology Executive and Drug Developer Kathryn Corzo as Chief Operating Officer

November 17, 2021

From Bit.bio

Via Business Wire

bit.bio Raises in Excess of $100 Million in First Close of Series B Financing

November 05, 2021

From bit.bio

Via Business Wire

bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate

October 28, 2021

From bit.bio

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.